Search results for "Hepatitis C virus"
High HCV cure rate seen with FDA-approved direct-acting antiviral regimens
Six of the direct-acting antiviral (DAA) regimens yielded sustained virologic response rates above 95% in patients who had hepatitis C virus (HCV) genotype 1 without cirrhosis, including those with HIV co-infection.
https://gastroenterology.acponline.org/archives/2017/03/24/7.htm
24 Mar 2017
8 weeks of ledipasvir/sofosbuvir may be effective for genotype 1 hepatitis C
The therapy should be considered in patients with genotype 1 infection who are treatment-naive, do not have cirrhosis, and have a pretreatment viral load below 6,000,000 IU/mL, a study found.
https://gastroenterology.acponline.org/archives/2017/03/24/2.htm
24 Mar 2017
Study finds substantial increase in HCV infection among younger women, children
Data from the National Notifiable Diseases Surveillance System and the Quest Diagnostics Health Trends database were used to estimate the incidence of hepatitis C virus (HCV) infection among women ages 15 to 44 years and children ages 2 to 13 years.
https://gastroenterology.acponline.org/archives/2017/05/26/1.htm
26 May 2017
HCV treatment appeared successful for patients who hadn't responded to previous direct-acting antivirals, industry-funded study finds
The study included two phase 3 trials: POLARIS-1, in which patients with chronic hepatitis C virus (HCV) had previously taken a regimen containing an NS5A inhibitor, and POLARIS-4, in which patients had previously received a direct-acting antiviral agent regimen that did not include an NS5A inhibitor.
https://gastroenterology.acponline.org/archives/2017/06/23/3.htm
23 Jun 2017
Review: In chronic hepatitis C virus infection, oral direct-acting antivirals have high sustained virologic response
A commentary in ACP Journal Club noted that while screening and treating all patients with chronic hepatitis C virus (HCV) would be cost-effective and probably cost-saving, some payers are still resistant.
https://gastroenterology.acponline.org/archives/2017/07/28/11.htm
28 Jul 2017
New HCV drug combo approved
The fixed-dose tablet combines the previously approved drugs sofosbuvir and velpatasvir with a new drug, voxilaprevir.
https://gastroenterology.acponline.org/archives/2017/07/28/10.htm
28 Jul 2017
Nearly all patients in study achieved sustained virologic response after 12 weeks of new HCV treatment
The drug combination appeared effective in adults with HCV genotypes 1, 2, 4, 5, or 6 infection and compensated cirrhosis in the industry-funded trial.
https://gastroenterology.acponline.org/archives/2017/08/25/3.htm
25 Aug 2017
HCV treatment by NPs, PCPs appears safe, effective as that provided by subspecialists
Reversing insurance restrictions that limit prescribing of direct-acting antivirals might allow rapid escalation of safe, effective therapy for hepatitis C virus (HCV) infection and could improve the care of patients, study authors noted.
https://gastroenterology.acponline.org/archives/2017/08/25/6.htm
25 Aug 2017
Spotlight on screening in primary care
Patient-specific reminders for clinicians performed best for increasing colorectal cancer screening in a French study, while an EHR alert appeared to successfully increase hepatitis C virus screening rates for baby boomers in a U.S. health care system.
https://gastroenterology.acponline.org/archives/2017/09/22/5.htm
22 Sep 2017
Project ECHO model appears cost-effective for HCV diagnosis, treatment
The incremental cost-effectiveness ratio with Project ECHO versus usual care was $10,351 per QALY, with 95.6% of iterations falling below a willingness-to-pay threshold of $50,000 per QALY and more than 99.9% falling below a willingness-to-pay threshold of $100,000 per QALY.
https://gastroenterology.acponline.org/archives/2017/11/28/3.htm
28 Nov 2017